Sobi® has announced a streamlining and simplification of the contractual economics for nirsevimab through a new royalty agreement with Sanofi and the termination of the participation agreement with AstraZeneca. In January 2019, Sobi completed the acquisition of Synagis® (palivizumab) from AstraZeneca in the US as well as the right to AstraZeneca’s full share of US profits and losses for nirsevimab. Synagis is a medicine used to help prevent a serious lung disease caused by respiratory syncytial virus (RSV) in children. Nirsevimab is under regulatory review in the US and recently approved in the EU for the prevention of RSV lower respiratory tract disease in new-borns and infants.
Latham & Watkins LLP represented Sobi in the transaction with a corporate deal team led by San Diego partner Steve Chinowsky, with London associate Oliver Mobasser. Advice was also provided on tax matters by Bay Area partner Kirt Switzer, with associate Alex Farris; and on antitrust matters by Bay Area partner Joshua Holian.
